The only way the doors stay open is with a lot of luck from China or Korea and soon. Unfortunately, I do not see that.
How about that SCILEX HOLDING bidding? I am not sure, but it seems no one wants it. No one really knows the statis of SEMDEXA which received Fast Track status from the FDA and 17 months after study completion has not applied for NDA. Having said that, you don't know what you don't know and for this personal piggy bank of the BOD there is little known. Vickers Vantage Corp. 1.6+ billion deal, lol, came in for about $120 million, bet they are happy. They knew more than the SRNE investors...maybe not. BP has connections in the FDA and NIH and I suspect knows the statis of it.
In any event the drone of "The Best is Yet to Come" and BUY, BUY, BUY has faded along with the stock price. This is not HERTZ who had assets and came out of BK in 14 months but since we are in the 7th month of C11 there is some room to hope.
OVYDSO STI-1558...
The Phase 3 study of Ovydso was initiated in China in February 2023 and enrolled and dosed 1,200 COVID-19 patients (1:1, active:placebo) at 25 sites in China. Covid is hitting the fully masked residents weaking Chinas economy as it burns its way through the population.
We (SORRENTO) anticipate top line data in the third quarter of this year (2023). Hey, it is the 3rd Quarter.
Should the Phase 3 trial be successful, we plan to open dialogue with regulatory agencies around the world to discuss paths to approval.
China represents, in many ways, SARS-CoV-2’s final frontier. With its under-vaccinated residents and sparse infection history, the nation harbors “a more susceptible population than really any other large population I can think of,” says Sarah Cobey, a computational epidemiologist at the University of Chicago. Soon, SARS-CoV-2 will infiltrate that group of hosts so thoroughly that it will be nearly impossible to purge again. “Eventually, just like everyone else on Earth, everyone in China should expect to be infected,” says Michael Worobey, an evolutionary virologist at the University of Arizona.
Dim light at the end of the tunnel...and the dim bulbs in the BOD room who got us here.
